Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: The Company manufactures and sells apparatus, instruments, devices, and consumables for life science research. The reporting period reflects a strategic shift toward organic growth and "tuck-under" acquisitions, highlighted by the acquisition of Denville Scientific, Inc. in September 2009. The Company divested its Capital Equipment Business segment in 2008, which is reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2008 |
|---|---|---|---|
| Revenues | $20,998 | $58,119 | $64,997 |
| Gross Profit | $10,229 | $28,581 | $30,528 |
| Gross Margin % | 48.7% | 49.2% | 47.0% |
| Operating Income | $1,930 | $5,086 | $4,897 |
| Net Income (Continuing Ops) | $1,321 | $3,441 | $3,703 |
| Net Income (Total) | $1,321 | $3,441 | $(403) |
| Cash and Equivalents | $14,645 | $14,645 | $11,658 |
| Long-Term Debt | $9,009 | $9,009 | $59 |
| Operating Cash Flow | N/A | $9,138 | $1,372 |
Note: All figures are in thousands except per share data and percentages. Net Income for the nine months ended Sep 30, 2008 includes a significant loss from discontinued operations.
Material Changes vs. Prior Period
- Revenue: For the nine months ended September 30, 2009, revenues decreased 10.6% to $58.1 million compared to $65.0 million in the prior year. This decline was primarily driven by a $5.4 million negative impact from foreign currency fluctuations (strengthening U.S. dollar) and a weaker economic environment. However, the acquisition of Denville Scientific contributed approximately $1.9 million in revenue.
- Profitability: Despite lower revenues, Gross Margin improved to 49.2% (from 47.0% in 2008) due to favorable sales mix, production efficiency improvements, and prior-year write-downs. Net income from continuing operations decreased slightly to $3.4 million from $3.7 million, but total net income improved significantly from a loss of $0.4 million in 2008 (which included a $4.1 million loss from discontinued operations).
- Debt and Liquidity: Long-term debt increased significantly to $9.0 million from $59 thousand, driven by borrowings to fund the Denville Scientific acquisition. Cash and cash equivalents increased to $14.6 million from $13.7 million at year-end 2008. Operating cash flow surged to $9.1 million (from $1.4 million in 2008) due to working capital improvements and higher net income.
- Acquisition: The Company acquired Denville Scientific, Inc. on September 2, 2009, for an estimated total purchase price of $25.3 million ($12.8 million cash paid initially, with $12.5 million contingent consideration).
Guidance, Outlook, and Risks
- Outlook: Management expects Denville Scientific to be a significant contributor to organic growth. The Company plans to continue investing in field sales and new product introductions (e.g., KDS Legato 200 syringe pump). Management believes current cash, operating cash flow, and debt capacity are sufficient to finance operations for 12 months and beyond.
- Restructuring: The Company recorded $0.6 million in restructuring charges for the nine months ended September 30, 2009, related to the relocation of the Scie-Plas operation and exit of general fabrication business. Remaining payments are expected in Q4 2009.
- Foreign Exchange Risk: Approximately 54% of revenues are derived from non-U.S. operations (primarily UK and Europe). A strengthening U.S. dollar negatively impacts reported revenues and earnings. The Company uses derivative instruments to hedge certain intercompany loans but does not designate them as accounting hedges.
- Capital Requirements: While current resources are adequate, the Company may need to raise additional capital (debt or equity) to pursue significant acquisitions beyond current capacity.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and revenue contribution of Denville Scientific, Inc., including the realization of the $12.5 million contingent consideration.
- Foreign Currency Exposure: Monitor the impact of the U.S. dollar strength against the British Pound and Euro on future revenue and earnings, given 54% of revenue is international.
- Debt Covenants: Confirm continued compliance with the amended $20 million revolving credit facility covenants (income, debt coverage, working capital) following the $9 million drawdown.
- Organic Growth Trends: Assess whether the flat organic growth in Q3 2009 is a temporary recessionary effect or a structural shift, excluding the impact of the Denville acquisition.
- Restructuring Completion: Track the completion of the 2009 restructuring plan and the associated cost savings in Q4 2009.